STEAP1 and prostate cancer: These findings establish that adding CBD-IL-12 as an adjunct to STEAP1 CAR T cell therapy may be beneficial through remodeling of the prostate cancer tumor microenvironment, enhancing antigen processing and presentation, and engaging host immunity to promote epitope spreading.